(Q37781296)

23 August 2017

MGMT promoter methylation in malignant gliomas (English)

1 reference

23 August 2017

3

Guido Reifenberger

1 reference

23 August 2017

Markus J Riemenschneider

series ordinal

1

1 reference

PubMed ID

20725792

23 August 2017

Monika E Hegi

series ordinal

2

1 reference

23 August 2017

20 August 2010

1 reference

23 August 2017

1 reference

23 August 2017

5

1 reference

23 August 2017

3

1 reference

23 August 2017

161-165

1 reference

https://scigraph.springernature.com/pub.10.1007/s11523-010-0153-6

23 August 2017

0 references

cites work

MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11523-010-0153-6

Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors.

21 January 2018

1 reference

12 December 2020

Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network

1 reference

12 December 2020

IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas

1 reference

12 December 2020

Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands

1 reference

12 December 2020

Validation of real-time methylation-specific PCR to determine O6-methylguanine-DNA methyltransferase gene promoter methylation in glioma.

1 reference

12 December 2020

Survival following adjuvant PCV or temozolomide for anaplastic astrocytoma

1 reference

12 December 2020

MGMT promoter methylation in malignant gliomas: ready for personalized medicine?

1 reference

12 December 2020

Anti-O6-methylguanine-methyltransferase (MGMT) immunohistochemistry in glioblastoma multiforme: observer variability and lack of association with patient survival impede its use as clinical biomarker.

1 reference

12 December 2020

Promoter Hypermethylation of the DNA Repair Gene O6‐Methylguanine‐DNA Methyltransferase is an Independent Predictor of Shortened Progression Free Survival in Patients with Low‐grade Diffuse Astrocytomas

1 reference

12 December 2020

IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group

1 reference

12 December 2020

Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas.

1 reference

12 December 2020

Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents

1 reference

12 December 2020

Identification of regions correlating MGMT promoter methylation and gene expression in glioblastomas

1 reference

12 December 2020

Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis

1 reference

12 December 2020

MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951.

1 reference

12 December 2020

Epigenetic mechanisms in glioblastoma multiforme

1 reference

12 December 2020

Prognostic significance of molecular markers and extent of resection in primary glioblastoma patients

1 reference

12 December 2020

Silencing effect of CpG island hypermethylation and histone modifications on O6-methylguanine-DNA methyltransferase (MGMT) gene expression in human cancer

1 reference

12 December 2020

Analysis of the IDH1 codon 132 mutation in brain tumors

1 reference

12 December 2020

Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma

1 reference

12 December 2020

IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas

1 reference

12 December 2020

Epigenetics of neurological cancers

1 reference

12 December 2020

NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide

1 reference

12 December 2020

Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UKT-03.

1 reference

12 December 2020

MGMT: its role in cancer aetiology and cancer therapeutics

1 reference

12 December 2020

MGMT gene silencing and benefit from temozolomide in glioblastoma

1 reference

12 December 2020

Phase II study of protracted daily temozolomide for low-grade gliomas in adults

1 reference

12 December 2020

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

1 reference

12 December 2020

10.1007/S11523-010-0153-6

Identifiers

DOI

1 reference

23 August 2017

1 reference

PubMed ID

20725792